Gland Pharma IPO GMP History
Gland Pharma IPO has been listed on November 20, 2020 at a listing price of ₹1710, against the issue price of ₹1500 — a gain of ₹210 (+14%). The GMP peaked at ₹170 on 4 November 2020 and reached a low of ₹25 on 11 November 2020. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Gland Pharma IPO raised ₹6479.55 Cr. through its IPO at a price band of ₹1490 to ₹1500 per share, with a lot size of 10 shares. The IPO was open for subscription from 09 Nov 2020 to 11 Nov 2020.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 11 Nov, 6:58 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 19 Nov 2020 | ₹ 110 | ▼ | 7% | — | — |
| 18 Nov 2020 | ₹ 130 | ▲ | 9% | — | — |
| 17 Nov 2020 | ₹ 120 | ▲ | 8% | — | — |
| 13 Nov 2020 | ₹ 70 | ▲ | 5% | — | — |
| 12 Nov 2020 | ₹ 50 | ▲ | 3% | — | — |
| 11 Nov 2020 | ₹ 25 | ▼ | 2% | — | — |
| 10 Nov 2020 | ₹ 30 | ▼ | 2% | — | — |
| 09 Nov 2020 | ₹ 60 | ▼ | 4% | — | — |
| 07 Nov 2020 | ₹ 70 | ▼ | 5% | — | — |
| 06 Nov 2020 | ₹ 90 | ▼ | 6% | — | — |
| 05 Nov 2020 | ₹ 130 | ▼ | 9% | — | — |
| 04 Nov 2020 | ₹ 170 | ▲ | 11% | — | — |
| 03 Nov 2020 | ₹ 160 | ▲ | 11% | — | — |
| 02 Nov 2020 | ₹ 150 | — | 10% | — | — |
Gland Pharma IPO dates
Key dates from opening to listing. Today is 13 November.
- Open 09 Nov 2020
- Close 11 Nov 2020
- Allotment 17 Nov 2020
- Refund/credit 18 Nov 2020
- Listing 20 Nov 2020
Gland Pharma IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹1500 |
|---|---|
| GMP-based estimate (pre-listing) | ₹1610 (+7.3%) |
| Listing gain / loss | +₹210 per share |
| Listing date | 20 Nov, 2020 |
| Actual listing price | ₹1710 (+14%) |
Is Gland Pharma IPO GMP reliable?
Grey market premium for Gland Pharma IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Gland Pharma IPO full review for a fundamentals-based assessment before making any grey market trades.
Gland Pharma IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Gland Pharma IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Gland Pharma IPO
Gland Pharma Limited was incorporated as Gland Pharma Private Limited at Hyderabad on 20 March 1978. Its promoters are Fosun Pharma Industrial Pte. Ltd. and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
According to the IQVIA Report in its RHP, it was one of the fastest growing generic injectables focused companies by revenue in the United States from 2014 to 2019. It sells mainly on a B2B model in over 60 countries, including the United States, Europe, Canada, Australia and India.
It works across the injectables value chain, from contract development and own development to dossier filing, technology transfer and manufacturing. Its products cover sterile injectables, oncology and ophthalmics, with a focus on complex injectables.
The IPO was Rs 6,479.55 crore, with Rs 1,250.00 crore of fresh issue and Rs 5,229.55 crore of offer for sale by Fosun Singapore and other shareholders. The fresh money was for working capital, capital expenditure and general purposes.
Frequently asked
What is the GMP of Gland Pharma IPO?
The current Grey Market Premium (GMP) of Gland Pharma IPO is ₹ 110.
What is the Kostak Price of Gland Pharma IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Gland Pharma IPO is not available.
What is the Subject to Sauda Price of Gland Pharma IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Gland Pharma IPO?
Gland Pharma IPO listed on November 20, 2020 at ₹1710, against the issue price of ₹1500 — a gain of +14%.
How did the GMP of Gland Pharma IPO trend before listing?
The GMP of Gland Pharma IPO was falling in its final days before listing. The GMP peaked at ₹170 on 4 November 2020. View the day-wise table above for the complete GMP history.
Explore Gland Pharma IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
